Sutro Biopharma, Inc. (STRO) is a publicly traded Healthcare sector company. As of September 29, 2026, STRO trades at $15.88 with a market cap of $264.97M and a P/E ratio of -0.60. STRO moved -1.40% today. Year to date, STRO is +38.55%; over the trailing twelve months it is +80.80%. Its 52-week range spans $5.23 to $43.85. Analyst consensus is strong buy with an average price target of $51.17. Rallies surfaces STRO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for STRO combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $15.88 |
| Market Cap | $264.97M |
| P/E Ratio | -0.60 |
| EPS | $-26.72 |
| Dividend Yield | 0.00% |
| 52-Week High | $43.85 |
| 52-Week Low | $5.23 |
| Volume | 11.56K |
| Avg Volume | 0 |
| Revenue (TTM) | $45.70M |
| Net Income | $-180.64M |
| Gross Margin | 0.00% |
8 analysts cover STRO: 0 strong buy, 7 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $51.17.